FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Increase in usage of DNA repair drugs as a combination therapy for improving treatment outcomes in ovarian and breast cancer is anticipated to propel the.
/PRNewswire/ Capsida Biotherapeutics Inc., an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies.